Back to Search
Start Over
Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, α-galactosylceramide
- Source :
-
Vaccine . Mar2008, Vol. 26 Issue 15, p1807-1816. 10p. - Publication Year :
- 2008
-
Abstract
- Summary: A number of studies have shown that the natural killer T cell (NKT) ligand α-galactosylceramide (α-GalCer) serves as an adjuvant for various vaccines, including viral vaccines, parasite vaccines and protein vaccines. In this report, we investigated the adjuvant activity of α-GalCer on HIV-1 DNA vaccines in mice. This is a first study to show that α-GalCer can enhance the immunogenicity of DNA vaccines, since co-administration of α-GalCer with suboptimal doses of DNA vaccines greatly enhanced antigen-specific CD4+ T-cell and CD8+ T-cell responses. Differently from other vaccines, α-GalCer was also able to enhance HIV-specific antibody response 10-fold. It is of practical importance to find out that, in a DNA prime-DNA boost regimen, the adjuvant activity of α-GalCer was most profound when co-administered at the priming, but not at the boosting phase. In a dose-sparing experiment, we found that the level of cell-mediated immune responses in mice vaccinated with 5μg of DNA in the presence of α-GalCer was equivalent to that of mice vaccinated with 50μg of DNA in the absence of α-GalCer. Finally, results from CD1d and interferon-γ receptor knockout mice confirm our previous data and determine the mechanistic dependence upon these molecules. These results illustrate that α-GalCer enhances the immunogenicity of DNA vaccines in a mechanism-based fashion. Since both mice and humans share the CD1d molecule, this information may aid in designing more effective DNA vaccines and vaccine adjuvants against HIV-1. [Copyright &y& Elsevier]
- Subjects :
- *DNA vaccines
*HIV
*IMMUNE response
*IMMUNOLOGICAL adjuvants
Subjects
Details
- Language :
- English
- ISSN :
- 0264410X
- Volume :
- 26
- Issue :
- 15
- Database :
- Academic Search Index
- Journal :
- Vaccine
- Publication Type :
- Academic Journal
- Accession number :
- 31407695
- Full Text :
- https://doi.org/10.1016/j.vaccine.2008.02.002